RxDoctor Payments DataLook up a doctor →

Subroto Bhattacharya, MD

Family Medicine · Peabody, MANPI 1053341685

Payments from drug & device makers

$11,813in general payments, 2019–2025

Across 638 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Lundbeck LLC$965
  • Pfizer$860
  • Novo Nordisk$763
  • Boehringer Ingelheim$701
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$11,49397%
  • Education$3203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,813 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$183,825
Medicare patients
271
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$103,831
TrulicityDulaglutide61$73,621
EliquisApixaban76$65,856
OzempicSemaglutide43$57,527
LinzessLinaclotide81$48,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$38,605
XareltoRivaroxaban41$36,336
MounjaroTirzepatide11$25,242
Breo ElliptaFluticasone/Vilanterol56$23,274
MyrbetriqMirabegron34$17,311
EntrestoSacubitril/Valsartan15$15,032
FarxigaDapagliflozin Propanediol22$14,502
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,628
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,529
TradjentaLinagliptin14$9,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$701$128,098123 claims
Lilly USA, LLCTrulicity, Mounjaro$668$98,86372 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$406$81,035132 claims
PfizerEliquis$860$65,85676 claims
Novo NordiskOzempic$763$57,52743 claims
AbbVieLinzess$1,281$48,34681 claims
Johnson & JohnsonXarelto$53$36,33641 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,145$30,52662 claims
Astellas Pharma US IncMyrbetriq$540$17,31134 claims
NovartisEntresto$134$15,03215 claims
Antares Pharma, Inc.Xyosted$84$7,85213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Peabody

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →